Table 3.
Summarized concentrations of phenothiazines inhibiting RNA virus replication.
| Virus | Drug | Concentration inhibiting viral replication [μM] | Source |
|---|---|---|---|
| DENV-2 | Prochlorperazine | EC50 = 137 nM | Simanjuntak et al. (2015) |
| MERS-CoV | Chlorpromazine | 12 μM (complete inhibition) | (Wilde et al. 2014) |
| SINV | Thioridazine | IC50 = 37.3 μM | Pohjala et al. (2011) |
| SFV | Chlorpromazine | IC50 = 15.7 μM | Pohjala et al. (2011) |
| Perphenazine | IC50 = 25.1 μM | Pohjala et al. (2011) | |
| Thioridazine | IC50 = 14.9 μM and 19.3 μM | Pohjala et al. (2011) | |
| ZEBOV-GFP | Chlorpromazine | 10 μg/ml i.e. 31.36 μM (complete inhibition) | Bhattacharyya et al. (2010) |
DENV-2 - Dengue virus serotype 2, MERS - Middle East respiratory syndrome, SFV - Semliki Forest virus, SINV - Sindbis virus, ZEBOV - GFP-expressing replication-competent EBOV Zaire.